Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference

/EIN News/ -- CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 2025 BIO CEO & Investor Conference. The conference will take place February 10-11, 2025, in New York, NY.

Details regarding Lifecore’s participation are as follows:

• 2025 BIO CEO & Investor Conference
  Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings
  Conference Dates: February 10-11, 2025
  Location: New York, NY

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Lifecore Biomedical, Inc. Contact Information:
                    
                    Vida Strategic Partners
                    Stephanie Diaz (Investors)
                    415-675-7401
                    sdiaz@vidasp.com 
                    
                    Tim Brons (Media)
                    415-675-7402
                    tbrons@vidasp.com 
                    
                    Ryan D. Lake (CFO)
                    Lifecore Biomedical
                    952-368-6244
                    ryan.lake@lifecore.com